Clinical trials
Locally Advanced or Metastatic Solid Tumors clinical trials
Below are recruiting locally advanced or metastatic solid tumors clinical trials, each written for real people, not researchers. We’re tracking 3,366 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07068971Enrolling by invitation
Sleep well at night for advanced cancer patients
This study tests a sleep program for people with advanced cancer who have trouble sleeping. It aims to help you sleep better at night.
DublinAges 18 years+ - NCT06650332RecruitingPhase 1/Phase 2
Cadonilimab combo for first-line HER2-positive gastric cancer
This trial tests a new combination treatment (cadonilimab plus chemotherapy) as the first therapy for people with advanced gastric or gastroesophageal junction cancer that has a certain amount of HER2 protein. It aims to see if this combination can shrink tumors and help people live longer.
Hangzhou, ZhejiangAges 18–75 - NCT04982276RecruitingPhase 1/Phase 2
Test new cancer drugs for advanced stomach or esophagus cancer
This Phase 1/2 study tests the safety and effectiveness of two investigational drugs (AK109 and AK104) in people with advanced stomach (or lower esophagus/GEJ) cancer. It’s for cases where the cancer did not respond to first-line treatment that included anti–PD-1/PD-L1 therapy plus chemotherapy.
BeijingAges 18–75 - NCT07586215Recruiting
HER2-targeted PET imaging to predict treatment response in advanced breast cancer
This trial tests whether a special type of PET scan can predict how well a targeted cancer drug (T-DXd) will work for patients with advanced breast cancer that has specific HER2 markers. The goal is to help doctors personalize treatment decisions based on imaging results.
ShanghaiAges 18 years+ - NCT05753306RecruitingPhase 2
Robot surgery plus heated chemo for limited spread stomach cancer
This study tests a “robot-assisted” surgery to remove stomach cancer in the belly lining (peritoneum) along with heated chemotherapy placed inside the abdomen. It’s for people whose cancer has spread only in the peritoneum, aiming to control disease when there’s a good chance of removing it all.
Rochester, MinnesotaAges 18–80 - NCT07303465RecruitingPhase 2
Testing a new drug for KRAS G12D pancreatic cancer
This trial tests a new experimental drug, RNK08954, for people with advanced pancreatic cancer that has a specific genetic change called KRAS G12D. The goal is to see if the drug is safe and can help shrink or slow the cancer.
NanjingAges 18–75 - NCT05984810RecruitingPhase 2
Using a glowing dye to help see pancreatic cancer during surgery
This trial tests whether a special dye (SGM-101) can help surgeons see remaining cancer cells during surgery for pancreatic cancer that has been treated before surgery. It may lead to more complete removal of the tumor.
LeidenAges 18 years+ - NCT06070740RecruitingPhase 2
Durvalumab Plus Chemo for Advanced Gastrointestinal NEC
This trial tests a combination of durvalumab (an immunotherapy drug) plus a chemotherapy called XELOX as the first treatment for advanced gastrointestinal neuroendocrine carcinoma (NEC). It aims to see if the combination works better than chemo alone.
Beijing, Beijing MunicipalityAges 18–75 - NCT06313086RecruitingPhase 3
New drug vs. T-DM1 for HER2-positive advanced breast cancer
This trial tests a new antibody-drug conjugate (DP303c) against an existing one, T-DM1, in people with HER2-positive advanced breast cancer who have already been treated with trastuzumab and a taxane. The goal is to see if the new drug works better or has fewer side effects.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07127822RecruitingPhase 2
Testing a new immunotherapy combo for MSI-H gastric cancer
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) for people with advanced gastric cancer that has a specific DNA repair problem (MSI-H/dMMR). It is for those who have not yet had any treatment for their advanced cancer.
Shijiazhuang, HebeiAges 18 years+ - NCT06062823RecruitingPhase 2
Newer EGFR pill for advanced lung cancer with specific mutations
This trial tests a newer type of EGFR targeted therapy pill for people with advanced non-small cell lung cancer who have not had prior treatment and whose cancer has a specific genetic change called a PACC mutation. The goal is to see if the drug works well for this group.
SingaporeAges 21–99 - NCT06123494RecruitingPhase 3
A trial of SHR-A1811 for HER2-positive gastric cancer
This trial tests a new drug, SHR-A1811, for people with HER2-positive stomach or gastroesophageal junction cancer that has worsened after initial treatment. It aims to see if this drug can help when standard anti-HER2 therapy stops working.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07497308Recruiting
GDF-15 levels and early outcomes after LVAD surgery
This trial looks at a blood marker called GDF-15 in people getting a heart pump (LVAD) to see if it can help predict early recovery or complications. It may help doctors better understand how patients will do after surgery.
Antalya, Please Select:Ages 18 years+ - NCT07467122RecruitingPhase 1
TCR-T cell therapy for MAGE-A4-positive sarcomas and other tumors
This trial tests a personalized cell therapy called TCR-T that targets a protein called MAGE-A4 on tumor cells. It is for people with advanced sarcomas or similar cancers that have not responded to standard treatments.
Guangzhou, GuangdongAges 18–75 - NCT07435701RecruitingPhase 1/Phase 2
Cell injection into belly for advanced ovarian cancer with fluid buildup
This trial tests a new type of therapy where special cells (called SK-NK cells) are injected directly into the belly to treat fluid buildup (ascites) caused by advanced ovarian cancer. It is for patients whose cancer has not responded to at least two prior treatments and who have no other standard options left.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07427992Recruiting
Study of zolbetuximab for stomach cancer with claudin 18.2
This trial is looking at a drug called zolbetuximab, given with chemotherapy, for people with a certain type of stomach or gastroesophageal junction cancer that has spread and has high levels of a protein called claudin 18.2. The goal is to see how well it works in real-world settings.
MilanAges 18–100 - NCT06892054RecruitingPhase 1
Targeted therapy plus chemo for advanced pancreatic cancer
This study tests a new targeted drug called sotorasib combined with standard chemotherapy for people with advanced pancreatic cancer that has a specific KRAS G12C mutation. The goal is to see if the combination works better than chemotherapy alone.
Avignon, FranceAges 18 years+ - NCT07235176RecruitingPhase 1/Phase 2
QLS1304 plus hormone therapy for ER+ breast cancer
This trial tests a new drug called QLS1304 combined with hormone therapy for people with ER-positive, HER2-negative breast cancer that has spread or come back and no longer responds to hormone therapy alone. The goal is to see if this combination can help shrink tumors or slow the disease.
ShanghaiAges 18 years+ - NCT07377643RecruitingPhase 3
New drug combo for advanced HER2-positive breast cancer
This trial tests a new drug called IBI354 (an antibody-drug conjugate) given with or without pertuzumab, compared to the standard combination of taxane, trastuzumab, and pertuzumab, for people with HER2-positive breast cancer that has spread and who have not had prior treatment for advanced disease.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05668650RecruitingPhase 3
Study MB12 versus Keytruda for newly diagnosed stage IV lung cancer
This Phase 3 trial compares MB12 with Keytruda (both cancer medicines) for people with newly diagnosed stage IV non-squamous non-small-cell lung cancer. It looks at whether MB12 can work as well or better than Keytruda, and compares safety and immune responses.
Viedma, Río Negro ProvinceAges 18 years+ - NCT05671822RecruitingPhase 2
Study of targeted drugs for HER2-positive advanced stomach cancer
This Phase 2 trial tests whether SHR-A1811—given with other medicines—works safely and effectively for people with advanced stomach or gastroesophageal junction cancer that has high HER2. It may help shrink tumors or slow cancer growth, especially if previous treatment didn’t work.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07367529RecruitingPhase 1/Phase 2
Study of TQB6411 for people with lung cancer
This trial tests a new drug called TQB6411 for people with lung cancer. It aims to see if the drug is safe and effective, and what side effects it might have.
Beijing, Beijing MunicipalityAges 18–75 - NCT06891742RecruitingPhase 1
A study of a new cell therapy for advanced liver cancer
This trial tests a new treatment called OriC902 for people with advanced liver cancer (HCC) that has not responded to standard therapies. The treatment uses special immune cells designed to target a protein called GPC3 found on cancer cells. The goal is to see if this approach can help shrink tumors or stop them from growing.
Beijing, Beijing MunicipalityAges 18–75 - NCT06828380RecruitingPhase 2
Immunotherapy with or without radiation for liver cancer
This trial tests whether using immunotherapy alone works as well as immunotherapy combined with radiation for liver cancer that has spread into major blood vessels. The goal is to find the best treatment option for people with this specific type of advanced liver cancer.
GoyangAges 19 years+
Hear when a new Locally Advanced or Metastatic Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for locally advanced or metastatic solid tumors?
- Yes. Clin2 currently lists 3,366 recruiting locally advanced or metastatic solid tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a locally advanced or metastatic solid tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a locally advanced or metastatic solid tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced (Unresectable) or Metastatic Solid Tumors
- Locally Advanced/Metastatic Solid Tumors
- Advanced or Metastatic Solid Tumors
- Advanced/Metastatic Solid Tumors
- Locally Advanced or Metastatic Breast Cancer
- Locally Advanced Solid Tumor
- Locally Advanced Malignant Solid Neoplasm
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.